To ask His Majesty's Government whether they have entered negotiations with AstraZeneca in relation to the cost of procuring Evusheld.

The Department has held regular discussions with AstraZeneca on the potential supply, procurement and cost of Evusheld. The Department continues to explore how further data about Evusheld’s effectiveness can be obtained, including encouraging AstraZeneca to continue discussions with the Antivirals and Therapeutics Taskforce on the potential for further research. Clinical advisers have recommended a United Kingdom clinical trial to generate sufficient data on Evusheld’s effectiveness against current and future variants, which is under consideration.